The use of GLP-1 receptor agonist and SGLT-2 inhibitors can exhibit cardioprotective effects without the risk of hypoglycemia even in acute condition such as AMI [44], thus making the intensified management of glucose more beneficial. Here, SLC5A2 is linked to Hypoglycemia.